As the most comprehensive, industry-focused and ‘must-attend’ event in the field, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches, perspectives, and data-drive case studies that will continue to advance PROTACs, molecular glues, and other degrader modalities towards clinical success.

With 70+ world-class speakers and over 500 senior attendees from around the globe, join the largest community of protein degradation experts for a deep dive into clinical development progress, lessons learnt and novel strategies to develop safe, selective and effective PROTACs, molecular glues, lysosomal degradation, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond.

Key Highlights:

• Evaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics, Arvinas, Nurix Therapeutics & Bristol Myers Squibb
• Deep dive into the methodologies of enhancing target engagement by improving target specificity, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly, FogPharma, GSK & Janssen
• Review the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers, Parkinsons, COVID-19 and AML with insights from Bristol Myers Squibb, Progenra & Origami Therapeutics
• Explore the different approaches to penetrating the blood brain barrier, comparing and contrasting the discovery, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra
• Outline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee, Ranok Therapeutics & Captor Therapeutics

To know more about 4th Targeted Protein Degradation Summit please click here.